Trial Information
Current as of August 02, 2025
Unknown status
Keywords
ClinConnect Summary
Approximately 20-30 million patients worldwide suffer from sepsis every year, which is increasing at the rate of 8% to 13% per year. It is possible that sepsis progress to multiple organ dysfunction in the early stage, with a fatality of 30% to 60%. Myocardium is one of the most vulnerable tissue under the abnormal 'inflammation storm'.Cardiac dysfunction is one of the important predictors for mortality of sepsis.Patients with myocardial depression have an apparently higher mortality rate (70%) as compared with septic patients without cardiac impairment (20%).
Although several trials had e...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- * Patiants meets the criteria of Sepsis 3.0 as below:
- • Sepsis is a lifethreatening organ dysfunction caused by a dysregulated host response to infection
- • 1 patients in ICU:
- • 1.1 have at least one organ dysfunction
- • 1.2 SOFA score ≥2
- • 2 patients not in ICU
- • 2.1 have at least one organ dysfunction
- • 2.2 SOFA score or qSOFA score ≥2
- Exclusion Criteria:
- • 1. Patient who is unable to comply with the follow-up schedule.
- • 2. Patient who has any medical conditions that in the opinion of the investigators will not be appropriate to participate in the study.
- • 3. Patient has a life expectancy of less than 6 months due to any condition
About Renji Hospital
Renji Hospital, a prestigious medical institution affiliated with Shanghai Jiao Tong University School of Medicine, is dedicated to advancing healthcare through innovative clinical research. With a strong emphasis on patient-centered care, Renji Hospital conducts a wide range of clinical trials across various therapeutic areas, harnessing cutting-edge technology and evidence-based practices. The hospital's multidisciplinary team of experienced researchers and medical professionals collaborates closely to ensure rigorous study design and execution, aiming to contribute significantly to medical knowledge and improve treatment outcomes for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials